UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada ...

Financial Data and Key Metrics Changes - For the fiscal year ended June 30, 2021, the company recorded a net loss of approximately $10 million or $1.52 per share, compared to a net loss of approximately $9 million or $1.71 per share for the previous year [34] - Cash and cash equivalents at the end of the year were approximately $7.4 million, an increase from approximately $5.8 million at the end of the previous fiscal year [37] Business Line Data and Key Metrics Changes - Research and development expenses for the year were approximately $5.3 million, a slight decrease from approximately $5.8 million in the previous year [35] - General and administrative expenses increased to approximately $4.5 million for fiscal year 2021, compared to approximately $3.2 million for the previous year [36] Market Data and Key Metrics Changes - BayMedica's initial product, Prodiol CBC, has generated cumulative revenues exceeding $2.5 million since sales began in December 2019, with an average growth of 35% quarter-on-quarter for the year ended June 30, 2021 [15] Company Strategy and Development Direction - The company announced a transformative acquisition of BayMedica, which specializes in the manufacturing and commercialization of rare cannabinoids, positioning InMed as a leader in this sector [9][12] - The IntegraSyn program achieved a pivotal milestone with an improved yield of 5 grams per liter, significantly exceeding industry standards, which supports the advancement to large-scale production [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming catalysts, including the closing of the BayMedica acquisition and the commencement of Phase 2 clinical trials for INM-755 [28][30] - The company is monitoring the decline in share price closely, attributing it to the overall market performance of cannabis companies, and is allocating resources to enhance investor relations [30] Other Important Information - The company is preparing for the integration of BayMedica, which is expected to accelerate commercial activities and revenue growth [18] - The IntegraSyn system is designed to produce pharmaceutical-grade cannabinoids efficiently, with plans to scale up production [22] Q&A Session Summary Question: What should be expected for revenues in fiscal year 2022 regarding the BayMedica acquisition? - Management indicated it is too early to provide specific revenue guidance for 2022 as the acquisition has not yet closed, but they expect growth based on historical performance [41][42] Question: How will the IntegraSyn business model play out? - The business model will depend on the specific cannabinoid being produced and its intended use, with a focus on optimizing manufacturing processes for cost-effectiveness [43][44] Question: What is the expected timeline for data release after enrollment completion for INM-755? - The treatment period is 28 days, followed by a one-week safety follow-up, with data expected to be available several months after the last patient completes the trial [47][48] Question: What is the rollout plan for additional cannabinoids from BayMedica? - Management stated that it is too early to provide specific timing for additional cannabinoid rollouts, as they need to assess integration and prioritize product launches [50][51] Question: What types of customers are purchasing the CBC product? - Currently, sales are primarily B2B, with customers including wholesale distributors and smaller manufacturers of cannabinoid-based products [54][56] Question: What is the timing for an IND filing for INM-088? - The company anticipates filing an IND in the later half of the next calendar year, pending completion of necessary toxicology studies [57][58]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 8 ...

InMed Pharmaceuticals Inc. (NASDAQ:INM) Q3 2021 Earnings Conference Call May 13, 2021 11:00 AM ET Company Participants Bruce Colwill - Chief Financial Officer Eric Adams - President and Chief Executive Officer Eric Hsu - Senior Vice President, Preclinical Research and Development Alexandra Mancini - Senior Vice President, Clinical and Regulatory Affairs Michael Woudenberg - Vice President, Chemistry, Manufacturing and Control Conference Call Participants Scott Henry - ROTH Capital Markets Operator Good morn ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of registrant as specified in its charter) British Columbia, Canada 98-1067994 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICA ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-1067994 (State or other jurisdiction of incorporation or organization) Suite 310 - 815 W. Hastings Street, Vancouver, B.C. (Address of Principal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the quarterly period ended September 30, 2020 or For the transition period from __________ to __________ Commission File Number: 001-39685 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-1067994 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Suite 310 - 815 W. Hastings Street, Vancouver, B.C. Canada V6C 1B4 (A ...

InMed Pharmaceuticals Inc. (IMLFF) Q4 2020 Earnings Conference Call September 8, 2020 11:30 AM ET Company Participants Brendan Payne - Director, Investor Relations Eric Adams - President & Chief Executive Officer Bruce Colwill - Chief Financial Officer Eric Hsu - Senior Vice President, Pre-Clinical Research & Development Alexandra Mancini - Senior Vice President, Clinical & Regulatory Affairs Conference Call Participants Maxim Jacobs - Edison Group Operator Good morning. My name is Veronica, and IÂ'll be yo ...

U N L O C K I N G T H E P O T E N T I A L O F C A N N A B I N O I D M E D I C I N E S Corporate Presentation September 2020 www.inmedpharma.com :IN :IMLFF Disclaimers This presentation does not constitute an offering to sell or a solicitation of an offer to buy securities and the information contained herein is subject to the information contained in the Company's continuous disclosure documents on SEDAR at www.sedar.com. Information concerning the assets and operations of the Company included in this prese ...